What Is the Treatment of Hypoparathyroidism?
Clinical Context
This protocol covers first-line conventional management of hypoparathyroidism. The central challenge is achieving and maintaining calcium levels within the target range while keeping a set of related biomarkers within safe limits.
Treatment Approach (Partial Overview)
Conventional treatment is built around an activated vitamin D analogue, titrated to calcium levels, combined with an adequate dietary elemental calcium intake. Further therapeutic components and the full prescribing algorithm — including sequencing, alternatives when first-choice agents are unavailable, and supplementation decisions — are detailed in the structured protocol.
Clinical Targets
- Serum calcium within the target range (lower part of, or slightly below, the reference range)
- Patient free of symptomatic hypocalcaemia
- Phosphate levels within the reference range
- Magnesium levels within the reference range
- Normal 24-hour urinary calcium excretion
- 25-hydroxyvitamin D level ≥ 75 nmol/L (≥ 30 ng/mL)
References
DOI: 10.1093/ejendo/lvaf222
- If available, we recommend treatment with an activated vitamin D analogue (e.g., alfacalcidol or calcitriol).
- We suggest a dietary elemental calcium intake of about 800–1000 mg/day in adults (non-pregnant) (European Food Safety Authority).
- We recommend titration of vitamin D analogue doses aiming at calcium levels within the target range with patients being free of symptomatic hypocalcaemia and biomarkers within the target range.
- We suggest aiming for phosphate levels within the reference range.
- We suggest aiming for magnesium levels within the reference range.
- We suggest aiming for normal 24-hour urinary calcium excretion.
- We suggest aiming at an adequate vitamin D status (25(OH)D level ≥ 75 nmol/L [> 30 ng/mL]).